E2F1 and gastric cancer: In our study, higher ANRIL could continuously activate CDK6 through repressing miR-449a and inactivate the p15INK4B/p16INK4A. These changes result in the inappropriate release of E2F1, consequently, gastric cancer cell proliferation.